# Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty

> **NCT04919135** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vinmec Research Institute of Stem Cell and Gene Technology** · enrollment: 158 (actual)

## Conditions studied

- Frailty

## Interventions

- **BIOLOGICAL:** Umbilical Cord Mesenchymal Stem Cells transplantation
- **DRUG:** standard frailty treatment and supplementary medication

## Key facts

- **NCT ID:** NCT04919135
- **Lead sponsor:** Vinmec Research Institute of Stem Cell and Gene Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-19
- **Primary completion:** 2023-04-20
- **Final completion:** 2024-12-30
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04919135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04919135, "Mesenchymal Stem/Stromal Cell Therapy in the Treatment of Frailty". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04919135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*